Trials / Completed
CompletedNCT04422457
Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 68Ga-DX600 PET/CT | DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning |
Timeline
- Start date
- 2020-06-13
- Primary completion
- 2022-03-01
- Completion
- 2022-03-01
- First posted
- 2020-06-09
- Last updated
- 2024-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04422457. Inclusion in this directory is not an endorsement.